Testing E-SYNC CAR T cell therapy for EGFRvIII positive glioblastoma
Original title: Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to check safety and dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a treatment made from a person's own immune cells.
Who this trial is for. This trial is for people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that is EGFRvIII positive. It tests E-SYNC CAR T cells given after chemotherapy that lowers immune cells.
Where it stands. The trial is checking safety, side effects, and the best dose. It has not reported results. We do not yet know if this treatment helps people.
What this means, and what it doesn't
What it could mean: T cells are taken from the blood and changed in a lab. They are then given back to the patient to attack cancer cells. Someone who fits this trial could ask their care team about it.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not proven care. Joining one is not a promise of any benefit. It is not a cure.
Source: ClinicalTrials.gov, August 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.